Cytokinetics - CYTK Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $57.71
Forecasted Upside: 73.00%
Number of Analysts: 12
Breakdown:
0 Sell Ratings
2 Hold Ratings
10 Buy Ratings
0 Strong Buy Ratings

^$33.36 As of 03/24/2023 01:00 AM ET

▼ -0.27 (-0.80%)

1 month | 3 months | 12 months

Get New Cytokinetics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for CYTK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYTK

^$57.71

▲ +73.00% Upside Potential

This price target is based on 12 analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $57.71, with a high forecast of $80.00 and a low forecast of $15.00. The average price target represents a 73.00% upside from the last price of $33.36.

Current Consensus is Buy

The current consensus among 12 investment analysts is to buy stock in Cytokinetics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
11 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/2/2021

0 strong buy ratings
13 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/31/2021

0 strong buy ratings
13 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/31/2022

0 strong buy ratings
13 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/29/2022

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/27/2022

0 strong buy ratings
8 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

12/26/2022

0 strong buy ratings
8 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

2/24/2023

0 strong buy ratings
10 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

3/26/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/7/2023	Cantor Fitzgerald	Reiterated Rating	Overweight	$61.00	N/A
3/6/2023	Mizuho	Initiated Coverage	Buy	$80.00	Low
3/2/2023	The Goldman Sachs Group	Lower Target	Buy	$56.00 ➝ $48.00	Low
3/2/2023	JMP Securities	Reiterated Rating	Buy	$71.00	Low
3/1/2023	Needham & Company LLC	Reiterated Rating	Buy	$58.00	Low
3/1/2023	Oppenheimer	Lower Target	Outperform	$55.00 ➝ $54.00	Low
2/17/2023	Bank of America	Initiated Coverage	Neutral	$49.00	Low
1/17/2023	The Goldman Sachs Group	Boost Target	Buy	$47.00 ➝ $56.00	Low
12/23/2022	Needham & Company LLC	Lower Target	Buy	$60.00 ➝ $58.00	Low
12/20/2022	Truist Financial	Initiated Coverage	Buy	$60.00	Low
12/16/2022	Mizuho	Initiated Coverage	Buy	$80.00	Low
12/15/2022	UBS Group	Lower Target	Neutral	$80.00 ➝ $66.00	Low
12/15/2022	The Goldman Sachs Group	Lower Target	Buy	$55.00 ➝ $47.00	Low
12/15/2022	HC Wainwright	Boost Target	Buy	$29.00 ➝ $56.00	Low
12/14/2022	Oppenheimer	Lower Target		$55.00	Low
12/14/2022	HC Wainwright	Lower Target		$75.00 ➝ $29.00	Low
12/14/2022	JMP Securities	Lower Target	Market Outperform	$82.00 ➝ $71.00	Low
12/9/2022	JPMorgan Chase & Co.	Lower Target		$64.00 ➝ $55.00	Low
12/8/2022	HC Wainwright	Reiterated Rating	Buy	$75.00	Low
10/11/2022	UBS Group	Initiated Coverage	Buy	$80.00	Low
10/3/2022	JMP Securities	Boost Target	Market Outperform	$53.00 ➝ $82.00	Low
9/2/2022	Mizuho	Initiated Coverage	Buy	$80.00	Low
8/15/2022	Cantor Fitzgerald	Boost Target		$56.00 ➝ $69.00	Low
8/12/2022	Morgan Stanley	Boost Target		$11.00 ➝ $15.00	Low
8/5/2022	Raymond James	Boost Target		$54.00 ➝ $63.00	Low
7/15/2022	Morgan Stanley	Boost Target	Overweight	$46.00 ➝ $60.00	Low
6/9/2022	Piper Sandler	Boost Target	Overweight	$50.00 ➝ $72.00	Medium
5/24/2022	HC Wainwright	Reiterated Rating	Buy	$75.00	Medium
5/24/2022	The Goldman Sachs Group	Lower Target	Buy	$71.00 ➝ $57.00	Low
5/16/2022	Mizuho	Boost Target	Buy ➝ Buy	$54.00 ➝ $80.00	Medium
5/5/2022	Needham & Company LLC	Boost Target		$52.00 ➝ $60.00	High
4/29/2022	HC Wainwright	Boost Target		$69.00 ➝ $75.00	High
2/17/2022	Cantor Fitzgerald	Lower Target		$57.00 ➝ $53.00	High
1/28/2022	The Goldman Sachs Group	Initiated Coverage	Buy	$74.00	High
12/21/2021	Oppenheimer	Initiated Coverage	Outperform	$55.00	High
12/21/2021	HC Wainwright	Boost Target	Buy	$62.00 ➝ $69.00	High
12/10/2021	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$58.00	Medium
12/1/2021	Mizuho	Boost Target	Buy	$45.00 ➝ $54.00	High
11/4/2021	HC Wainwright	Boost Target	Positive ➝ Buy	$58.00 ➝ $62.00	High
11/4/2021	JMP Securities	Reiterated Rating	Buy		High
10/12/2021	Cantor Fitzgerald	Boost Target	Overweight	$48.00 ➝ $57.00	Low
10/8/2021	HC Wainwright	Reiterated Rating	Buy	$58.00	Medium
10/8/2021	Morgan Stanley	Boost Target	Overweight	$38.00 ➝ $45.00	Medium
10/6/2021	Jefferies Financial Group	Initiated Coverage	Buy	$75.00	High
9/7/2021	Barclays	Boost Target	Overweight	$40.00 ➝ $45.00	High
8/9/2021	Piper Sandler	Lower Target	Overweight	$42.00 ➝ $40.00	Low
8/6/2021	HC Wainwright	Boost Target	Buy	$53.00 ➝ $58.00	High
7/20/2021	Cantor Fitzgerald	Boost Target	Positive ➝ Overweight	$35.00 ➝ $48.00	High
7/20/2021	Barclays	Boost Target	Overweight	$28.00 ➝ $40.00	High
7/19/2021	JMP Securities	Boost Target	Outperform ➝ Outperform	$26.00 ➝ $44.00	High
7/19/2021	Raymond James	Boost Target	Outperform	$37.00 ➝ $54.00	High
7/19/2021	Piper Sandler	Boost Target	Positive ➝ Overweight	$25.00 ➝ $42.00	High
7/19/2021	HC Wainwright	Boost Target	Buy	$41.00 ➝ $53.00	High
7/19/2021	Needham & Company LLC	Boost Target	Buy	$33.00 ➝ $48.00	High
7/1/2021	Mizuho	Initiated Coverage	Buy	$36.00	Low
5/11/2021	Mizuho	Boost Target	Buy	$26.00 ➝ $36.00	Medium
4/19/2021	Morgan Stanley	Boost Target	Overweight	$24.00 ➝ $35.00	Low
3/11/2021	Wolfe Research	Initiated Coverage	Outperform	$50.00	High
2/18/2021	Barclays	Initiated Coverage	Overweight	$28.00	High
1/20/2021	HC Wainwright	Boost Target	Buy	$22.00 ➝ $41.00	High
12/16/2020	Morgan Stanley	Boost Target	Overweight	$22.00 ➝ $24.00	Low
12/14/2020	Mizuho	Lower Target	Buy	$31.00 ➝ $26.00	High
11/24/2020	Raymond James	Reiterated Rating	Buy		High
11/23/2020	HC Wainwright	Lower Target	Buy	$43.00 ➝ $22.00	High
11/16/2020	Needham & Company LLC	Reiterated Rating	Buy	$33.00	Medium
11/16/2020	Morgan Stanley	Lower Target	Overweight	$24.00 ➝ $22.00	High
10/28/2020	The Goldman Sachs Group	Initiated Coverage	Neutral	$16.00	Low
10/12/2020	Morgan Stanley	Lower Target	Overweight	$35.00 ➝ $24.00	Low
10/8/2020	HC Wainwright	Lower Target	Positive ➝ Buy	$59.00 ➝ $43.00	High
10/6/2020	Cantor Fitzgerald	Boost Target	Overweight	$41.00 ➝ $48.00	Medium
7/23/2020	Piper Sandler	Boost Target	Overweight	$33.00 ➝ $36.00	Low
7/23/2020	HC Wainwright	Boost Target	Buy	$38.00 ➝ $59.00	Low
7/15/2020	Cantor Fitzgerald	Boost Target	Overweight	$29.00 ➝ $41.00	High
7/15/2020	JMP Securities	Boost Target	Outperform	$23.00 ➝ $29.00	High
7/14/2020	Needham & Company LLC	Boost Target	Buy	$34.00 ➝ $45.00	High
7/14/2020	Piper Sandler	Boost Target		$28.00 ➝ $33.00	High
7/14/2020	HC Wainwright	Boost Target	Buy	$35.00 ➝ $38.00	High
7/10/2020	Raymond James	Initiated Coverage	Strong-Buy	$39.00	High
7/7/2020	Morgan Stanley	Boost Target	Overweight	$29.00 ➝ $35.00	High
5/23/2020	Mizuho	Initiated Coverage	Buy	$31.00	Low
5/12/2020	Morgan Stanley	Boost Target	Overweight	$25.00 ➝ $29.00	Low
5/11/2020	HC Wainwright	Boost Target	Positive ➝ Buy	$30.00 ➝ $35.00	High
5/7/2020	Needham & Company LLC	Reiterated Rating	Buy	$24.00	Low
5/4/2020	Mizuho	Initiated Coverage	Buy	$31.00	High
4/27/2020	Morgan Stanley	Reiterated Rating	Buy	$25.00	Low
4/24/2020	HC Wainwright	Reiterated Rating	Buy		Medium
4/19/2020	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight		Low
4/17/2020	Cantor Fitzgerald	Boost Target	Overweight	$12.00 ➝ $23.00	High
4/14/2020	HC Wainwright	Reiterated Rating	Buy	$30.00	Medium
4/14/2020	Needham & Company LLC	Reiterated Rating	Buy	$24.00	Low
4/9/2020	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$14.00 ➝ $25.00	High
3/31/2020	HC Wainwright	Reiterated Rating	Buy	$30.00	High
3/4/2020	Needham & Company LLC	Reiterated Rating	Buy	$24.00	Medium
2/26/2020	HC Wainwright	Reiterated Rating	Buy	$30.00	Low
2/7/2020	HC Wainwright	Reiterated Rating	Buy		High
11/1/2019	Needham & Company LLC	Reiterated Rating	Buy	$24.00	High
10/4/2019	Needham & Company LLC	Reiterated Rating	Buy	$16.00	Low
10/4/2019	HC Wainwright	Reiterated Rating	Buy	$26.00	Medium
9/16/2019	Piper Jaffray Companies	Reiterated Rating	Overweight	$14.00 ➝ $20.00	High
9/13/2019	JMP Securities	Set Target	Buy	$23.00	Medium
9/6/2019	Cantor Fitzgerald	Reiterated Rating	Overweight	$14.00 ➝ $20.00	Medium
8/9/2019	Needham & Company LLC	Set Target	Buy	$16.00	Medium
8/9/2019	Morgan Stanley	Set Target	Hold	$16.00	Medium
7/15/2019	Morgan Stanley	Set Target	Hold	$11.00	High
7/15/2019	Piper Jaffray Companies	Set Target	Buy	$14.00	High
5/10/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$14.00	Medium
5/6/2019	HC Wainwright	Boost Target	Buy	$21.00 ➝ $26.00	Medium
4/23/2019	HC Wainwright	Set Target	Buy	$21.00	High
3/20/2019	Piper Jaffray Companies	Boost Target	Overweight	$12.00 ➝ $13.00	High
3/19/2019	HC Wainwright	Reiterated Rating	Buy	$21.00	High
1/22/2019	HC Wainwright	Reiterated Rating	Buy	$21.00	Medium
12/5/2018	HC Wainwright	Set Target	Buy	$21.00	Low
12/5/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$14.00	Low
11/27/2018	HC Wainwright	Reiterated Rating	Buy	$21.00	Low
11/2/2018	HC Wainwright	Set Target	Buy	$21.00	High
11/2/2018	Cantor Fitzgerald	Set Target	Buy	$14.00	High
10/17/2018	HC Wainwright	Set Target	Buy	$21.00	High
10/17/2018	Cantor Fitzgerald	Set Target	Buy	$14.00	High
10/5/2018	HC Wainwright	Lower Target	Buy ➝ Buy	$24.00 ➝ $21.00	Low
10/5/2018	Morgan Stanley	Set Target	Hold	$10.00	High
10/3/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$14.00	High
9/20/2018	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$14.00	High
9/10/2018	Morgan Stanley	Initiated Coverage	Equal Weight ➝ Equal Weight	$10.00	Medium
8/1/2018	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$18.00 ➝ $9.00	High
7/27/2018	HC Wainwright	Set Target	Buy	$24.00	High
6/18/2018	HC Wainwright	Boost Target	Buy	$24.00	High
6/18/2018	Piper Jaffray Companies	Lower Target	Overweight	$13.00	High
6/17/2018	Cantor Fitzgerald	Reiterated Rating	Hold	$10.00	High
4/27/2018	HC Wainwright	Reiterated Rating	Buy	$20.00	High
4/24/2018	Cantor Fitzgerald	Set Target	Hold	$10.00	Low

(Data available from 3/26/2018 forward)

News Sentiment Rating

0.94 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

1 very positive mentions
12 positive mentions
3 negative mentions
1 very negative mentions

Mentions as of

8/28/2022

3 very positive mentions
5 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

9/27/2022

5 very positive mentions
14 positive mentions
3 negative mentions
1 very negative mentions

Mentions as of

10/27/2022

4 very positive mentions
2 positive mentions
1 negative mentions
2 very negative mentions

Mentions as of

11/26/2022

5 very positive mentions
11 positive mentions
0 negative mentions
3 very negative mentions

Mentions as of

12/26/2022

7 very positive mentions
5 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/25/2023

11 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/24/2023

14 very positive mentions
9 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

3/26/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

finance.yahoo.com
3/1/2023
FDA Rejects Cytokinetics' Heart Failure Treatment Candidate

Negative

No negative mentions tracked during this time.

Positive

marketbeat.com
3/24/2023
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Average Rating of "Moderate Buy" by Analysts
finance.yahoo.com
3/20/2023
Cytokinetics Reports Fourth Quarter 2022 Financial Results
markets.businessinsider.com
3/18/2023
Mizuho Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)
marketbeat.com
3/6/2023
Cytokinetics, Incorporated (NASDAQ:CYTK) Expected to Earn FY2023 Earnings of ($4.51) Per Share
finance.yahoo.com
3/3/2023
Industry Analysts Just Upgraded Their Cytokinetics, Incorporated (NASDAQ:CYTK) Revenue Forecasts By 15%

Very Positive

marketbeat.com
3/23/2023
Bank of New York Mellon Corp Increases Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)
marketbeat.com
3/22/2023
Yousif Capital Management LLC Sells 13,145 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)
marketbeat.com
3/21/2023
Teachers Retirement System of The State of Kentucky Invests $2.27 Million in Cytokinetics, Incorporated (NASDAQ:CYTK)
marketbeat.com
3/19/2023
Peregrine Capital Management LLC Increases Stock Position in Cytokinetics, Incorporated (NASDAQ:CYTK)
marketbeat.com
3/17/2023
Insider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Sells 12,500 Shares of Stock

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Today's Range

Now: $33.36

$32.96

$33.64

50 Day Range

MA: $41.17

$33.36

$45.71

52 Week Range

Now: $33.36

$32.96

$55.80

Volume

720,685 shs

Average Volume

1,182,978 shs

Market Capitalization

$3.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.85

Frequently Asked Questions

What sell-side analysts currently cover shares of Cytokinetics?: The following equities research analysts have issued research reports on Cytokinetics in the last twelve months: Bank of America Co., Cantor Fitzgerald, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, StockNews.com, The Goldman Sachs Group, Inc., Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for CYTK.
What is the current price target for Cytokinetics?: 14 Wall Street analysts have set twelve-month price targets for Cytokinetics in the last year. Their average twelve-month price target is $57.71, suggesting a possible upside of 73.0%. Mizuho has the highest price target set, predicting CYTK will reach $80.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $15.00 for Cytokinetics in the next year.
View the latest price targets for CYTK.
What is the current consensus analyst rating for Cytokinetics?: Cytokinetics currently has 2 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CYTK will outperform the market and that investors should add to their positions of Cytokinetics.
View the latest ratings for CYTK.
What other companies compete with Cytokinetics?: Other companies that are similar to Cytokinetics include Amicus Therapeutics, Reata Pharmaceuticals, PTC Therapeutics, IVERIC bio and Maravai LifeSciences. Learn More about companies similar to Cytokinetics.
How do I contact Cytokinetics' investor relations team?: Cytokinetics' physical mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company's listed phone number is (650) 624-3000 and its investor relations email address is [email protected] The official website for Cytokinetics is www.cytokinetics.com. Learn More about contacing Cytokinetics investor relations.

Cytokinetics - CYTK Stock Price Target and Predictions

Analyst Price Target for CYTK

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.94 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Cytokinetics?

What is the current price target for Cytokinetics?

What is the current consensus analyst rating for Cytokinetics?

What other companies compete with Cytokinetics?

How do I contact Cytokinetics' investor relations team?